Cases

23-15-cv Do No Harm v. Pfizer In the United States Court of Appeals For the Second Circuit August Term, 2023 (Argued: October 3, 2023 Decided: January 10, 2025) Docket No. 23-15 DO NO HARM, Plaintiff-Appellant,

23-15-cv Do No Harm v. Pfizer In the United States Court of Appeals For the Second Circuit ______________ August Term, 2023 (Argued: October 3, 2023 Decided: March 6, 2024) Docket No. 23-15 ______________

Anthony W. Ishii, SENIOR DISTRICT JUDGE The case stems from the death of Agapita Marroquin after she had taken the generic prescription drug amiodarone. Plaintiff Gilbert Marroquin, Mrs. Marroquin's husband, brings seven claims under California law against Defendants Pfizer, Inc. ("Pfizer") and Mylan Institutional, Inc. ("Mylan") for strict products liability, negligence

MEMORANDUM AND ORDER Sterling Johnson, Jr., Senior U.S.D.J. Plaintiffs Matthew Fermín, Lichun Huo, Josefina Valdez, and Adriana Sousa (“Plaintiffs”) bring this action against Defendant Pfizer Incorporated (“Pfizer” or “Defendant”) pursuant to the Federal Food Drug & Cosmetic Act (“FDCA”), 21 U.S.C. § 352 et seq., and New York, Florida and California state consumer laws. In short, in this “slack-fill”

ARNOLD, Circuit Judge. Elaine Robinson is one of 64 women from 29 states who sued Pfizer in a Missouri state court, asserting state-law claims that arose from Pfizer’s manufacture and sale of the drug Lipitor, which they allege causes diabetes. Pfizer removed the ease to federal district court, 1 maintaining that the ca

Gary Feinerman, United States District Judge On behalf of themselves and a putative nationwide class, Karmel Al Haj and Timothy Woodhams allege in this diversity suit that Pfizer Inc., which markets and distributes Robitussin cough syrup, deceives consumers by charging more for "Maximum Strength" Robitussin even though it contains a lower concentration of one of its two active ingredients than does "Regular Strength" Robitussin. Doc

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MSP RECOVERY CLAIMS, SERIES LLC, et al., Plaintiffs, No. 22-cv-01419 (DLF) v. PFIZER, INC., et al., Defendants. MEMORANDUM OPINION This case, brought by multiple limited liability companies formed for litigation purposes, involves an

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MSP RECOVERY CLAIMS, SERIES LLC et al., Plaintiffs, v. No. 22-cv-1419 (DLF) PFIZER, INC. et al., Defendants. MEMORANDUM OPINION Five limited liability companies—MSP Recovery Claims, Series LLC; MSP Recovery Claims PROV,

*646CASE MANAGEMENT ORDER NO. 55 Richard Mark Gergel, United States District Court Judge In this MDL, Plaintiffs allege that Lipitor caused them to develop Type 2 diabetes. To carry their burden, Plaintiffs must prove both general and specific causation. Westberry v. Gislaved Gummi AB, 178 F.3d 257, 263 (4th Cir.1999). The Court will address

KRAUSER, C.J. The issue before us is whether Pfizer Inc., appellee, may be deemed an “apparent manufacturer” of an asbestos-containing cement, “Insulag,” which purportedly caused the illness and subsequent death of Carl Stein from mesothelioma. The product at issue was manufactured and sold to Mr. Stein’s employer, Bethlehem Steel Corpo

PER CURIAM: In this diversity action, Plaintiff Neal M. Jacobson appeals the district court’s dismissal of his pro se amended complaint against Defendant Pfizer, Inc. (“Pfizer”) pursuant to Federal Rule of Civil Procedure 12(b)(6) for failure to state a claim. After review, we affirm. In 2012, Jacobson pled guilty in Florida state court to the first degree murder of his wife and two children and

OPINION AND ORDER J. PAUL OETKEN, District Judge: In May 2012, Georgia resident Joyce Benefield sought treatment for a post-operative abdominal infection. She was prescribed Tygacil, an antibacterial drug manufactured by Pfizer and its subsidiary Wyeth Pharmaceuticals, for the infection. After she began taking the drug, Joyce says that she developed a number of conditions, including vasculitis,

MEMORANDUM AND ORDER ROSLYNN R. MAUSKOPF, District Judge. Plaintiffs Matt Kardovich, Lila Chui, and Cindy Chang bring a putative class action grounded in various state statutory and common law claims, alleging that defendant Pfizer, Inc. has engaged in pervasive and deceptive labeling of Centrum branded multivitamins. (Am. Class Action Compl. (Doc. No. 13).)' Before the Court is defendant’s ful

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE PFIZER INC., Plaintiff, ) ) ) V. ) C.A. No. N18C-01-310 PRW CCLD ) ARCH INSURANCE COMPANY ) AND U.S. SPECIALTY INSURANCE ) COMPANY, ) Defendants. _) Submitted: April 1, 2019 Decided: July 23, 2019 Upon Plaintiff's Motion for Partial Summary Judgment, GRANTED. Upon Defendants’ Motion for Partial Summary Judgment, DENIED. MEMORANDUM OPINION AND ORDER John P. Ditomo, Esquire, Kenneth J. Nachbar, Esquire, Barnaby Grzaslewicz, Esquire, Morris, Nic

MEMORANDUM OPINION ROBINSON, District Judge I. INTRODUCTION On October 22, 2015, Pfizer Inc., Wyeth LLC, Pfizer Pharmaceuticals LLC, PF PRISM C.Y., and Pfizer Manufacturing Holdings. LLC, (collectively “plaintiffs”) filed a complaint alleging infringement of three patents related to its injectable antibiotic product TYGACIL® (“Tygacil”) against defendants Mylan Inc., Mylan N.V., Mylan Labo

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MSP RECOVERY CLAIMS, SERIES LLC, et al., Plaintiffs, No. 22-cv-01419 (DLF) v. PFIZER, INC., et al., Defendants. MEMORANDUM OPINION Five limited liability corporations—MSP Recovery Claims, Series LLC; MSP Re

LOUGHRY, Justice: *236 The petitioners (plaintiffs below), J.C., a minor by and through his mother and next friend Michelle C., and I.H., a minor by and through her mother and next friend, Angela H., appeal the order of the Mass Litigation Panel ("Panel") entered on February 15, 2017, throug

OPINION AND ORDER GEORGE C. SMITH, District Judge. Plaintiff Chris Geiger brings this action pursuant to the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, 29 U.S.C. § 1132. On March 9, 2010, Plaintiff moved for judgment on the administrative record (Doc. 47) against Defendant CIGNA Life Insurance Company of New York (“CIGNA-NY”), alleging an unlawful termination of benefit

Order, Supreme Court, Bronx County (John A. Barone, J.), entered on or about December 27, 2012, which, to the extent appealed from, denied the motion of Jones Lang LaSalle Americas Inc. (JLL) for summary judgment dismissing the complaint as against it, unanimously reversed, on the law, without costs, summary judgment granted and the complaint dismissed as to defendant JLL. The Clerk is directed to enter judgment accordingly. A contractu

OPINION AND ORDER JOHN V. ACOSTA, United States Magistrate Judge. : Introduction Plaintiff Kimberly Arnold (“Arnold”) brings this employment lawsuit against defendant Pfizer, Inc. (“Pfizer”) arising from a prior employment relationship. Arnold alleges claims of discrimination and retaliation under Title I of the Americans with Disabilities Act (“the ADA”), 42 U.S.C. § 12101